Kiniksa Q3 ARCALYST rev $33.4M, total rev $99.1M, net income $224.1M on tax benefit

Kiniksa Pharmaceuticals International, plc

2022-Q3 EPS reported $2.55 revenue$158,296,000

ARCALYST net revenue $33.4M in Q3 2022; full-year guidance reaffirmed at $115-130M.
Total revenue $99.1M, including $65.7M from vixarelimab license with Genentech.
Net income $224.1M vs net loss $30.5M YoY; includes $177.4M tax benefit from valuation allowance release.
Cash and equivalents $200.7M, no debt; expected to fund operations into at least 2025.
RHAPSODY LTE data: rilonacept beyond 18 months reduced recurrence risk 98.2% (HR=0.018, p<0.0001).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Kiniksa Pharmaceuticals International, plc reported Third Quarter 2022 results: revenue $99.1 million, net income $224.1 million.

Period: Third Quarter 2022
Revenue: $99.1 million
Net income: $224.1 million
Result: reported results

Exact text from the filing

Total revenue for the third quarter of 2022 was $99.1 million, compared to $12.1 million for the third quarter of 2021. - Total revenue for the third quarter of 2022 included $33.4 million in ARCALYST net product revenue and $65.7 million in license and collaboration revenue from the vixarelimab global license agreement with Genentech. Kiniksa did not report license and collaboration revenue in the third quarter of 2021. · Total operating expenses for the third quarter of 2022 were $52.7 million, compared to $42.8 million for the third quarter of 2021. - Total operating expenses for the third quarter of 2022 included $4.6 million in collaboration expense. Kiniksa did not report collaboration expense in the third quarter of 2021. - Total operating expenses for the third quarter of 2022 included $6.0 million of non-cash, share-based compensation expense, compared to $6.2 million for third quarter of 2021. · Net income for the third quarter of 2022 was $224.1 million, compared to a net lo

View on SEC.gov

Browse all earnings releases →

Kiniksa Pharmaceuticals International, plc filing history →

Source: SEC EDGAR

accession 0001104659-22-113204

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.